. [eighty two] to assess the efficacy, security and tolerability of Cannabidiol being an adjunct therapy together with anti-epileptic drugs on the people suffering from tuberous sclerosis complex whose most common neurological symptom is epilepsy. With this scientific trial review, soon after remedy with Cannabidiol, responder fee of the patients s